Advanced search
Publication Cover
Emerging Drugs Volume 5, 2000 - Issue 2
Journal homepage
13
Views
0
CrossRef citations to date
0
Altmetric
Review

Cancer vaccines

R Todd Reilly Department of Oncology, The John Hopkins University School ofMedicine, Baltimore, MD 21231, USA.
,
Jean-Pascal H Machiels Department of Oncology, The John Hopkins University School ofMedicine, Baltimore, MD 21231, USA.
&
Elizabeth M Jaffee Department of Oncology, The John Hopkins University School ofMedicine, Baltimore, MD 21231, USA.
Pages 201-209 | Published online: 24 Feb 2005

Bibliography

  • DRANOFF G, JAFFEE E, LAZENBY A, et al.: Vaccinationwith irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90(8):3539–3543.
  • GOLUMBEK PT, LAZENBY AJ, LEVITSKY HI, et al.:Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 254(5032):713–716.
  • BASKAR S, OSTRAND-ROSENBERG S, NABAVI N, et al.:Constitutive expression of B7 restores irnnaunogen-icity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA (1993) 90(12):5687–5690.
  • CHEN L, ASHE S, BRADY WA, et al Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 71(7):1093–1102.
  • TOWNSEND SE, ALLISON JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 259(5093):368–370.
  • OSTRAND-ROSENBERG S, ROBY C, CLEMENTS VK, et al.: Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes. Int. J. Cancer Suppl. (1991) 6:61–68.
  • PLAUTZ GE, YANG ZY, Wu BY et al.: Imnaunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA (1993) 90(10):4645–4649.
  • WALLICH R, BULBUC N, HAMMERLING GJ, et al Abroga- tion of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature (1985) 315(6017):301–305.
  • PARDOLL DM: Paracrine cytokine adjuvants in cancer irnnaunotherapy. Ann. Rev. Immunol. (1995) 13:399–415.
  • GANSBACHER B, ZIER K, DANIELS B, et al.: Interleukin 2 gene transfer into tumor cells abrogates tunaorigen-icity and induces protective immunity. J. Exp. Med. (1990) 172(4):1217–1224.
  • PORGADOR A, TZEHOVAL E, KATZ A, et al Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res (1992) 52(13):3679–3686.
  • PULASKI BA, MCADAM AJ, HUTTER EK, et al.: Interleukin3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res. (1993) 53(9):2112–2117.
  • HARRIS JE, RYAN L, HOOVER HC, JR. et al.: Adjuvant active specific irnmunotherapy for stage II and BI colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. (2000) 18(1):148–157.
  • ••Randomised Phase III Trial (n = 412) of autologous tumorcell vaccine with BCG adjuvant. While no statistical benefit was seen in patients receiving vaccine, when treatment compliance was taken into account, trends towards increased disease-free and overall survival were seen.
  • LEONG SP, ENDERS-ZOHR P, ZHOU YM, et al.: Recombi- nant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J. Immunother. (1999) 22(2):166–174.
  • SIMONS JW, JAFFEE EM, WEBER CE, et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 57(8):1537–1546.
  • SIMONS JW, MIKHAK B, CHANG JF, et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res (1999) 59(20):5160–5166.
  • PALMER K, MOORE J, EVERARD M, et al.: Gene therapywith autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum. Gene Ther. (1999) 10(8):1261–1268.
  • SCHREIBER S, KAMPGEN E, WAGNER E, et al.: Immuno-therapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a Phase I study. Hum Gene Ther. (1999) 10(6):983–993.
  • SOBOL RE, SHAWLER DL, CARSON C, et al.: Interleukin 2gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin. Cancer Res. (1999) 5(9):2359–2365.
  • MOLLER P, SUN Y, DORBIC T, et al.: Vaccination with IL-7gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical Phase I study. Br. J. Cancer (1998) 77(10:19074916.
  • ETON O, KHARKEVITCH DD, GIANAN MA, et al.: Activeirnmunotherapy with ultraviolet B-irradiated autolo-gous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin. Cancer Res. (1998) 4(3):619–627.
  • KUGLER A, SESEKE F, THELEN P, et al Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br. J. Urol. (1998) 82(4):487–493.
  • ARIENTI F, BELLI F, NAPOLITANO F, et al Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum Gene Ther. (1999) 1O(18):2907–2916.
  • HSUEH EC, NATHANSON L, FOSHAG LJ, et al.: Active specific irnmunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer (1999) 85(10):2160–2169.
  • ••Relatively large Phase II Trial (n = 54) using an allogeneicvaccine that targets several defined melanoma antigens simultaneously. A complete remission was seen in 7 of 54 patients.
  • SOIFFER R, LYNCH T, MIHM M, et al.: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (1998) 95 (22): 13141–13146.
  • JAFFEE EM, ABRAMS R, CAMERON J, et al A Phase I clinical trial of lethally irradiated allogeneic pancre-atic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther. (1998) 9(13):1951–1971.
  • WOODLOCK TJ, SAHASRABUDHE DM, MARQUIS DM, et al Active specific irnmunotherapy for metastatic colorectal carcinoma: Phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. J Immunother. (1999) 22(3):251–259.
  • THOMAS MC, GRETEN TF, PARDOLL DM, et al.: Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum. Gene Ther. (1998) 9(6):835–843.
  • TOES RE, BLOM RJ, VAN DER VOORT E, et al.: Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res. (1996) 56(16):3782–3787.
  • JERNE NK: Towards a network theory of the immune system. Ann. Immunol. (Paris) (1974) 125C(1-2):373–389.
  • FOON KA, LUTZKY J, BARAL RN, et al.: Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol. (2000) 18(4:376–384.
  • •Encouraging results were seen using TriGem vaccine (Titan Pharmaceuticals, Inc.) with QS-21 adjuvant (Aquila Biophar-maceuticals, Inc.). A Phase III Trial is possible.
  • DURRANT LG, BUCKLEY DJ, ROBINS RA, et al.: 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses. Int. J. Cancer (2000) 85(1):87–92.
  • SAMONIGG H, WILDERS-TRUSCHNIG M, KUSS I, et al A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibodyvaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer. J. Immunother. (1999) 22(6):481–488.
  • FOON KA, SEN G, HUTCHINS L, et al.: Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialogang,lioside GD2. Clin. Cancer Res. (1998) 4(5):1117–1124.
  • GRANT SC, KRIS MG, HOUGHTON AN, et al.: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Caknette-Guerin. Clin. Cancer Res. (1999) 5(6)1319–1323.
  • MCCAFFERY M, YAO TJ, WILLIAMS L, et al.: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 gang,lioside: enhanced immunogenicity when combined with adjuvant. Clin. Cancer Res. (1996) 2(4):679–686.
  • YAO TJ, MEYERS M, LIVINGSTON PO, et al.: Immuniza-tion of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin. Cancer Res. (1999) 5(1):77–81.
  • REINARTZ S, BOERNER H, KOEHLER S, et al.: Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines - a prelimi-nary report. Hybridoma (1999) 18(1):41–45.
  • STEINMAN RM, COHN ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. (1973) 137(5):1142–1162.
  • ADEMA GJ, HARTGERS F, VERSTRATEN R, et al A dendritic-cell-derived C-C chemokine that preferen-tially attracts naive T cells. Nature (1 9 9 7) 387(6634):713–717.
  • ROMANI N, GRUNER S, BRANG D, et al.: Proliferating dendritic cell progenitors in human blood. J. Exp. Med. (1994) 180(1)83–93.
  • SIENA S, DI NICOLA M, BREGNI M, et al.: Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp. Hematol. (1995) 23(14):1463–1471.
  • STEINMAN RM: The dendritic cell system and its role in knmunogenicity. Ann. Rev. Immunol. (1991) 9:271–296.
  • MAYORDOMO JI, ZORINA T, STORKUS WJ, et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. (1 9 9 5) 1(12)1297–1302.
  • ZITVOGEL L, MAYORDOMO JI, TJANDRAWAN T, et al.: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimula-don and T helper cell 1-associated cytokines [see comments]. J. Exp. Med. (1996) 183(1):87–97.
  • PAGLIA P, CHIODONI C, RODOLFO M, et al.: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo [see comments]. J. Exp. Med. (1996) 183(1):317–322.
  • GONG J, CHEN D, KASHIWABA M, et al Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med (1997) 3(5):558–561.
  • BOCZKOWSKI D, NAIR SK, SNYDER D, et al.: Dendriticcells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. (1996) 184(2):465–472.
  • SONG W, KONG HL, CARPENTER H, et al: Dendritic cellsgenetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protec-tive and therapeutic antitumor immunity. J. Exp. Med. (1997) 186(8):1247–1256.
  • SPECHT JM, WANG G, DO MT, et al.: Dendritic cellsretrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. (1 9 9 7) 186(8):1213–1221.
  • THURNER B, HAENDLE I, RODER C, et al.: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. (1999) 190(11):1669–1678.
  • •Regressions seen in 6 of 11 patients after vaccination with melanoma antigen-pulsed DC. An increased number of antigen-specific CD8+ T-cells in 8 of 11 patients.
  • NESTLE FO, ALIJAGIC S, GILLIET M, et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [see comments]. Nature Med. (1998) 4(3):328–332.
  • •Two complete responses and three partial responses were seen in a group of 16 patients. Tumour-specific immune responses were seen in 11 of 16 patients.
  • MORSE MA, DENG Y, COLEMAN D, et al.: A Phase I study of active knmunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. (1999) 5(6):1331–1338.
  • SALGALLER ML, LODGE PA, MCLEANJG et al Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate (1 9 9 8) 3 5(2) 144–151
  • TJOA BA, SIMMONS SJ, ELGAMAL A, et al.: Follow-up evaluation of a Phase II prostate cancer vaccine trial. Prostate (1999) 40(2):125–129.
  • CHAKRABORTY NG, SPORN JR, TORTORA AF, et al Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother. (1998) 47(1):58–64.
  • HOLTL L, RIESER C, PAPESH C, et al Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol (1999) 161(3)777–782.
  • BRONTE V, TSUNG K, RAO JB, et al.: IL-2 enhances thefunction of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. (1995) 154(10):5282–5292.
  • IRVINE KR, MCCABE BJ, ROSENBERG SA, et al: Syntheticoligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J Immunol (1995) 154(9):4651–4657.
  • MCCABE BJ, IRVINE KR, NISHIMURA MI, et al.: Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lympho-cyte responses. Cancer Res. (1995) 55(8):1741–1747.
  • RESTIFO NP, BACIK I, IRVINE KR, et al.: Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. (1995) 154(9):4414–4422.
  • WANG M, BRONTE V, CHEN PW, et al.: Active immuno-therapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. (1995) 154(9):4685–4692.
  • LIN KY, GUARNIERI FG, STAVELEY-O'CARROLL KF, et al.: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. (1996) 56(1):21–26.
  • WU TC GUARNIERI FG STAVELEY-O'CARROLL KF , et al.:Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. USA (1995) 92(25):11671–11675.
  • CONRY RM, KHAZAELI MB, SALEH MN, et al Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarci-noma: comparison of intradermal versus subcuta-neous administration. Clin Cancer Res (1999) 5(9):2330–2337.
  • CONRY RM, ALLEN KO, LEE S, et al.: Human autoanti-bodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin. Cancer Res. (2000) 6(1)34–41.
  • MARSHALL JL, HAWKINS MJ, TSANG KY, et al.: Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. (1999) 17(1):332–337.
  • ZHU MZ, MARSHALL J, COLE D, et al.: Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. (2000) 6(1):24–33.
  • •The induction of CD8+ T-cells capable of recognizing and lysing tumour cells was seen after vaccination.
  • ROSENBERG SA, ZHAI Y, YANG JC, et al.: Immunizing patients with metastatic melanoma using recombi-nant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. (1998) 90(24):1894–1900.

Websites

  • http://www.cancer.org American Cancer Society website - cancer statistics obtained from here.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.